Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 4, 2007, Pages 416-423

  Paganelli, Massimiliano ^a   Albanese, Carlina ^a   Borrelli, Osvaldo ^a   Civitelli, Fortunata ^a   Canitano, Nicoletta ^a   Viola, Franca ^a   Passariello, Roberto ^a   Cucchiara, Salvatore ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Inflammatory bowel disease; Infliximab; Osteoporosis; Pediatrics

Indexed keywords

INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BODY MASS; BONE DENSITY; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BONE DENSITY; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; GASTROINTESTINAL AGENTS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PROSPECTIVE STUDIES;

EID: 34247567769     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20039     Document Type: Article

References (44)

1. Bachrach LK. Dual energy X-ray absorptiometry (DXA) measurements of bone density and body composition: promise and pitfalls. J Pediatr Endocrinol. 2000;13(Suppl 2):983-988.
2. Fewtrell MS, Gordon I, Biassoni L, et al. Dual X-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: Does the method of size-adjustment matter? Bone. 2005;37:413-419.
3. Bjarnason I, Macpherson A, Macintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut. 1997;40:228-233.
4. Schoon EJ, van Nunen AB, Wouters R, et al. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol. 2000;35:43-47.
5. Semeao EJ, Jawad AF, Stouffer NO, et al. Risk factors for low bone mineral density in children and young adults with Crohn's disease. J Pediatr. 1999;135:593-600.
6. Levine A, Mishna L, Ballin A, et al. Use of Quantitative Ultrasound to Assess Osteopenia in Children With Crohn Disease. J Pediatr Gastroenterol Nutr. 2002;35:169-172.
7. Gokhale R, Favus MF, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology. 1998;114:902-911.
8. Boot AM, Bouquet J, Krenning EP, et al. Bone mineral density and nutritional status in children with inflammatory bowel disease. Gut. 1998;42:188-194.
9. Ahmed SF, Horrocks IA, Patterson T, et al. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J Pediatr Gastroenterol Nutr. 2004;38:276-281.
10. Herzog D, Bishop N, Glorieux F, et al. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis. 1998;4:261-267.
11. Cowan FJ, Warner JT, Dunstan FJ, et al. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child. 1997;76:325-329.
12. Issenman RM, Atkinson SA, Rodja C, et al. Longitudinal assessment of growth, mineral metabolism and bone mass in pediatric Crohn's disease. J Pediatr Gastroenterol Nutr. 1993;17:401-406.
13. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410-415.
14. Pullman WE, Elsbury S, Kobayashi M, et al. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology. 1992;102:529-537.
15. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res. 2002;17:695-702.
16. Cohen-Solal ME, Graulet AM, Denne MA, et al. Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab. 1993;77:1648-1653.
17. König A, Mühlbauer RC, Fleish H. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary (3H) tetracycline excretion from labelled mice. J Bone Miner Res. 1988;3:621-627.
18. Kumar S, Votta BJ, Rieman DJ, et al. IL-1β and TNF-α induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001;187:294-303.
19. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001;276:563-568.
20. Fuller K, Murphy C, Kirstein B, et al. TNF alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology. 2002;143:1108-1118.
21. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology. 2000;141:3956-3964.
22. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A. 2000;97:1566-1571.
23. Ryan BM, Russel MGV, Schurgers L, et al. Effect of antitumour necrosis factor - a therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther. 2004;20:851-857.
24. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol. 2005;100:2031-2035.
25. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol. 2006;40:55-63.
26. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and the Wrist, 2nd ed. Stanford, Calif: Stanford Press; 1959.
27. Kroger H, Kotaniemi A, Vainio P, et al. Bone densitometry of the spine and femur in children by dual-energy x-ray absorptiometry. Bone Miner. 1992;17:75-85. Erratum in: Bone Miner. 1992;17:429.
28. Kroger H, Vainio P, Nieminem J, et al. Comparison of different models for interpreting bone mineral density measurement using DXA and MRI technology. Bone. 1995;17:157-159.
29. Van der Sluis IM, de Ridder MAJ, Boot AM, et al. Refence data for bone density and body composition measured with dual energy x ray absorptiometry in white children and young adults. Arch Dis Child. 2002;87:341-347.
30. Semeao EJ, Jawad AF, Zemel BS, et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis. 1999;5:161-166.
31. Varghese S, Wyzga N, Griffiths AM, et al. Effects of serum from children with newly diagnosed Crohn's disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr. 2002;35:641-648.
32. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al. Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab. 2001;86:2032-2042.
33. Bernstein CN, Seeger LL, Sagre JW, et al. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res. 1995,10:250-256.
34. Jahnsen J, Falch JA, Aadland E, et al. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 1997;40:313-319.
35. Abitbol V, Roux C, Chaussade S, et al. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology. 1995;108:417-422.
36. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol. 1997;92:1157-1163.
37. Silvennoinen JA, Karttunen TJ, Niemela SE, et al. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995;37:71-76.
38. Ghosh S, Cowen S, Hannan WJ, et al. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031-1039.
39. Staun M, Tjellesen L, Thale M, et al. Bone mineral content in patients with Crohn's disease: a longitudinal study in patients with bowel resection. Scand J Gastroenterol. 1997;32:226-232.
40. Ammann P, Rizzoli R, Bonjour J-P, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest. 1997;99:1699-1703.
41. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology. 2005;44:1546-1548.
42. Tobiume H, Kanzaki S, Hida S, et al. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy. J Clin Endocrinol Metab.. 1997;82:2056-2061.
43. Behnke B, Kemper M, Kruse H, et al. Bone alkaline phosphatase in children with chronic renal failure. Nephrol Dial Transplant. 1998;13:662-667.
44. Sylvester F, Davis P, Wyzga N et al. Are activated T cells regulators of bone metabolism in children with Chron disease? J Pediatr. 2006;148:461-466.